Deanol aceglumate - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation

Noocleolin®

solution inwards

PIK-PHARMA, LLC Russia

АТХ:

N.06.B.X Other psychostimulants and nootropic drugs

Pharmacodynamics:

Nootropic drug, by chemical structure is close to natural metabolites of the brain (γ-aminobutyric acid, glutamic acid). It is also a precursor of choline, which is why it enhances the formation of acetylcholine. Has cerebroprotective effect, restores mental activity, improves learning, facilitates the processes of fixation, consolidation and reproduction of a memorable trace, stimulates tissue metabolism processes, improves ability to concentrate attention, positively influences neurotic states of senile age that develop against the background of organic brain insufficiency, with alcohol abstinence syndrome.

Pharmacokinetics:

It has high bioavailability. After 0.5-1 hour after oral administration, it is detected in the maximum concentration in the brain, liver, kidneys, blood plasma, heart. The therapeutic concentration in the central nervous system is reached in 30-60 minutes after taking the drug. Half-life is 24 hours. Eliminated by the kidneys.

Indications:

- Intellectual-mnestichesky infringements;

- Tardive dyskinesia;

- Neuroleptic syndrome;

- Psychosomatic disorders;

- Alcohol withdrawal syndrome;

- Astheno-depressive conditions;

- Vascular diseases of the brain;

- The period of convalescence after a head trauma.

ICD-10

V.F00-F09.F07 Personality and behavioral disorders due to illness, damage or dysfunction of the brain

V.F00-F09.F07.2 Postcontasia syndrome

V.F00-F09.F07.9 Organic personality and behavioral disorder due to illness, damage or dysfunction of the brain, unspecified

V.F10-F19.F10.2 Mental and behavioral disorders caused by alcohol use - addiction syndrome

V.F10-F19.F10.3 Mental and behavioral disorders caused by alcohol use - withdrawal symptoms

V.F20-F29.F20 Schizophrenia

V.F20-F29.F21 Chrysotile disorder

V.F20-F29.F22 Chronic delusional disorders

V.F20-F29.F23 Acute and transient psychotic disorders

V.F20-F29.F25 Schizoaffective disorder

V.F20-F29.F29 Inorganic psychosis, unspecified

V.F30-F39.F32 Depressive episode

V.F30-F39.F34.1 Dysthymia

V.F40-F48.F45 Somatoform disorders

V.F50-F59.F51.1 Drowsiness [hypersomnia] inorganic etiology

IX.I60-I69.I67.2 Cerebral atherosclerosis

IX.I60-I69.I69 Effects of cerebrovascular disease

XI.K70-K77.K70 Alcoholic liver disease

XI.K70-K77.K72.0 Acute and subacute liver failure

XI.K70-K77.K73 Chronic hepatitis, not elsewhere classified

XI.K70-K77.K74.6 Other and unspecified liver cirrhosis

XI.K70-K77.K76.0 Fatty degeneration of the liver, not elsewhere classified

XI.K80-K87.K83.1 Blockage of the bile duct

Contraindications:

Hypersensitivity, febrile states, psychotic conditions, epilepsy, pregnancy and lactation, infectious diseases of the central nervous system, blood diseases, chronic liver and kidney diseases, age up to 10 years.

Carefully:

In the period of treatment, abstinence from driving vehicles and controlling mechanisms is required, and one should refrain from occupations that are potentially dangerous and require special concentration of attention.

Pregnancy and lactation:

Category FDA not determined. Adequate and well-controlled studies on humans and animals have not been conducted. Do not apply.

Dosing and Administration:

Inside for 1 g (one teaspoon) 2-3 times a day; the last reception - no later than 16-18 hours. The average daily intake for adults is 4-6 g.The maximum single dose is 2 g, the maximum daily dose is 10 g; the duration of treatment is 1.5-2.5 months 2-3 times a year.

Side effects:

Hypersensitivity, depression (in people over 65 years), headaches, sleep disorders, constipation, weight loss, itching.

Overdose:

Increased side effects. Treatment is symptomatic.

Interaction:

With simultaneous reception with funds that stimulate the central nervous system, potentiation of the action of the drug is possible.

Special instructions:

At the time of taking the drug, it is necessary to observe the neurologist, monitoring the electroencephalogram.

Instructions

Deanola aceglumate (Deanoli aceglumas)